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Purpose: We conducted the present retrospective study to elucidate regional differences in the quality of secondary screening in the 
prostate cancer (PCA) screening program by a local municipality in Japan.
Methods: Of 115,881 men who attended the PCA screening in 36 municipalities between 2001 and 2011, a total of 6,099 men consulted 
hospitals for secondary screening. The cancer detection rate (CDR) at the secondary screening was calculated, and municipalities were 
classified into three CDR groups according to the age-adjusted observed-to-expected ratios of CDR. Of the secondary screening facilities, 
hospitals in Ibaraki Prefecture screening less than 100 patients were classified as group I facilities and the others as group II facilities. 
Results: Overall, 2,320 of 6,099 secondary screening patients underwent prostate biopsy, and 1,073 men were diagnosed with PCA. 
The overall CDR at the secondary screening was 17.6%, but it varied from 5.6% to 34.4% among municipalities. Although there were no 
significant differences in age and prostate-specific antigen (PSA) distribution among the three CDR groups, a significantly higher rate 
of patients in low CDR municipalities visited group I facilities. Both biopsy rates and CDRs of secondary screening at group II facilities 
were significantly higher than those of group I facilities (P=0.0001). Multivariate analysis showed that the secondary screening at group 
II facilities as well as age and PSA levels were independent contributing factors for PCA detection. 
Conclusions: CDRs at secondary screening varied widely among municipalities in Ibaraki Prefecture. Variation in CDRs was 
associated with biopsy rates.
Keywords: Prostate neoplasms, Prostate-specific antigen, Early detection of cancer
Prostate Int 2014;2(1):19-25 • http://dx.doi.org/10.12954/PI.13035
Original Article
Corresponding author: Hiroyuki Nishiyama
Department of Urology, University of Tsukuba Faculty of Medicine, 2-1-1 Amakubo, Tsukuba 305-0005, Japan 
E-mail: nishiuro@md.tsukuba.ac.jp / Tel: +81-29-853-3223 / Fax: +81-29-853-8854 
Submitted: 21 December 2013 / Accepted after revision: 4 February 2014
INTRODUCTION
Prostate cancer (PCA) is one of the common malignancies 
in men. The number of PCA patients increasing, and PCA is 
expected to become the second most frequent male cancer in 
Japan. Further, the PCA mortality rate will increase by 2.8 folds 
in 2020 compared to 2000 [1]. This increase of prevalence rate 
is affected by various factors including age of the population, 
food, genetic factors, and also screening systems using pros-
tate-specific antigen (PSA). PCA was generally identified by 
metastatic symptoms before the PSA era, but the introduction 
of PSA made it possible to identify PCA in the early stages. 
 Generally, prevention and early detection reduce the mor-
tality rate of malignancies. For this reason, national popula-
tion-based screening systems have been established in Japan 
for five major malignancies including lung, stomach, breast, 
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in the PSA-based screening program. In the first screening, 
the serum PSA level alone with a cut off of 4.0 ng/mL was 
used, and notifications for further examinations were mailed 
to participants by the Ibaraki Health Service Association 
(IHSA). When the participants were referred to hospital or 
clinics for secondary screening, each facility sent the results of 
further examinations to IHSA using the screening report form. 
The available information from the screening report including 
examination date, patient age, name of the facility, PSA levels 
at secondary screenings, and the results of a prostate biopsy if 
performed. The percentage of individuals referred for second-
ary screening and CDR were aggregated annually for each 
municipality by IHSA. We obtained permission of IHSA com-
mittee for use of anonymised data on PCA screening in the 
present study. 
2. Patients and facilities
Because the aggregate screening data is available from 2001, 
we analyzed the results of 115,881 men who attended a PSA-
based screening for the first time between 2001 and 2011. Dur-
ing this period, as a result of municipal mergers, 84 munici-
palities in Ibaraki Prefecture were integrated into 44 munici-
palities. Therefore, we adjusted the data of each municipality 
according to the consequence of these municipal mergers. 
 In the present study, we excluded men who had previously 
attended the PSA-based screening program of Ibaraki Prefec-
ture. Among 115,881 men, 8,473 men (7.3%) had a serum PSA 
level higher than 4.0 ng/mL at the first screening, and finally 
a total of 6,099 (72.0%) received the secondary screening. The 
profiles of these 6,099 patients are presented in Table 1. During 
the study period, a total of 376 hospitals or clinics conducted 
the secondary screening. Of them, 299 facilities were located in 
Ibaraki Prefecture and the remaining 77 facilities were located 
outside of Ibaraki Prefecture. We divided these facilities into 
two groups according to number of patients screened during 
the study period. The hospitals or clinics with less than 100 pa-
tients in 10 years were classified as group I facilities. Those with 
100 or more patients and those located outside Ibaraki Prefec-
ture were classified as group II facilities. Thus, 240 facilities and 
136 facilities were classified as group I and group II facilities, 
respectively. 
3. Statistical analysis
CDR at secondary screening, the rates of prostate biopsies 
performed and positive biopsy rates were calculated using 
the following equations: 
CDR at secondary screening = number of PCA patients/
number of patients who received secondary screening
colon, and cervical cancer. PSA-based screening systems for 
PCA have not been established by the Japanese government, 
but mostly administered by municipal governments since the 
1990s. The Japanese Urological Association (JUA) recommends 
PSA-based screening for men over 50 years old, and also fur-
ther examinations for patients with more than 4 ng/mL or age-
adjusted cut off levels of PSA to assess the presence of PCAs 
[2]. Further examinations including digital rectal examinations, 
transrectal ultrasonography, blood examinations, magnetic 
resonance imaging, and/or prostate biopsy are performed as 
secondary screening. The definitive diagnosis of PCA is made 
by prostate biopsy, although the actual indication for a biopsy 
largely depends on decision-making practices at each facility.
 The cancer detection rate (CDR) is an important indicator 
to evaluate screening systems for malignancies. CDR of PSA-
based screening is known to be higher than those of national 
screening systems for the other five major cancers. Accord-
ing to a survey by the Japan Cancer Society, the CDR of PCA 
screening was 0.5% in 2011, whereas those of the other five 
cancer screenings were 0.04% to 0.22%. However, large re-
gional differences in the CDRs of PCA screening were report-
ed; the 2005 annual report of the Japanese Foundation for 
Prostate Research (JFPR) revealed that the CDR among men 
attending a primary screening varied from 0.0% to 5.1% in 218 
municipalities throughout Japan [3]. Multiple factors, includ-
ing the age distribution of the target population, exposure 
rates of PSA screening, rate of persons receiving secondary 
screening, quality of secondary screening, and others might 
be responsible for the variability. Comprehensive analysis of 
these factors might reveal strategies to improve the CDR, but 
this type of information is limited in Japan. Improvement of 
CDR is considered to be a common issue in most of Asian 
countries, where PSA exposure rates are very lower than 
Western countries [4]. In the present study, we extensively 
analyzed factors contributing to regional differences in CDRs 
at the secondary screening using the practice-based, retro-
spective data of 115,881 men who participated in PSA-based 
screening programs of Ibaraki Prefecture during the past 10 
years. Ibaraki Prefecture is located about 100 km from Tokyo. 
To our knowledge, this is the first study to examine factors re-
sponsible for regional differences in CDRs of PCA screening 
programs by municipal governments in Japan. 
MATERIALS AND METHODS
1. PSA-based screening program in Ibaraki Prefecture
PSA screening was started in Ibaraki Prefecture in 1999, and 
36 of 44 municipalities in Ibaraki Prefecture have participated 
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ware package JMP ver. 10.0.2 (SAS Institute, Cary, NC, USA).
RESULTS
Among 6,099 men who received the secondary screening, a 
total of 2,320 (38.0%) underwent prostate biopsy, and 1,073 
men were finally diagnosed with PCA (Table 1). The CDR of 
all participants in the secondary screening was 17.6%. When 
CDRs were calculated by municipality, large differences in 
CDRs were noted: they varied from 5.6% to 35.0%. Even when 
CDRs in each municipality were adjusted by age-population, 
the age-adjusted O/E ratios of PCA patients varied from 0.39 
to 2.40, as shown in Fig. 1. 
 To examine the possible factors contributing to the differ-
ence in CDRs, 36 municipalities were divided into three groups 
according to their O/E ratios. Thus, 14, 11, and 11 municipali-
ties were classified as high, moderate, and low CDR groups 
(Fig. 1), and their CDRs were 22.8%, 17.0%, and 12.8%, respec-
tively. Among the three groups divided by CDR, there was no 
significant difference in the distribution of age and PSA (Fig. 2). 
On the other hand, more patients belonging to the moderate 
and low CDR groups rather than the high CDR group tended to 
visit group I facilities (P=0.05 and P=0.001, respectively)
 Next, we compared qualities of secondary screening be-
tween groups I and II facilities. As shown in Fig. 3A, the CDR 
of group II facilities was significantly higher than that of group 
I facilities in total (21.0% and 10.7%, respectively; P= 0.0001). 
When participants were divided into high, moderate, and 
low CDR groups, similar significant differences in CDRs be-
tween groups I and II facilities were observed in all three CDR 
groups (Fig. 3). The rates of prostate biopsies were significant-
ly different between groups I and II facilities, although there 
were no significant differences in positive biopsy rates. Mul-
tivariate analysis demonstrated that group I/II facilities, as 
well as age and PSA levels, were independent factors for CDR 
Prostate biopsy rate=number of patients who underwent 
prostate biopsy/number of patients who received second-
ary screening
Positive biopsy rate = number of PCA patients/number of 
patients who underwent prostate biopsy 
 The age-adjusted observed-expected (O/E) ratio of PCA 
patients in each municipality was calculated by the number of 
screening detected PCA patients in the municipality divided by 
its expected number. The expected number of PCA patients 
was calculated by applying the age-specific CDRs in Ibaraki 
Prefecture to the age-specific populations in each municipal-
ity. The age-specific CDRs in Ibaraki Prefecture was calculat-
ed from accumulated PCA screening data between 2001 and 
2011. We classified 36 municipalities into three regions (high, 
moderate, low) by tertiles of the OER. 
 Differences in the factors related to CDRs at secondary 
screening (age, serum PSA level, type of facility) were exam-
ined by a simple logistic regression (Table 2). Differences in 
CDR, biopsy rate, and positive biopsy rate between facilities 
were examined by a chi-square test. Multivariate analyses us-
ing a logistic regression model were performed to examine the 
contributing factors associated with cancer detection (Table 
2). P-values of less than 0.05 were considered statistically sig-
nificant. All statistical analyses were performed using the soft-
Table 1. Participants profile in secondary screening
Variable Value
No. of municipality 36
No. of secondary screenees 6,099
Biopsied cases, n (%) 2,320 (38.0)
No. of prostate cancer 1,073
Positive biopsy proportion 46.3%
CDR in secondary screening 17.6%
Distribution of age, n (%)
≤59 440 (7.2)
60–69 2,631 (43.1)
70–79 2,564 (42.0)
≥80 464 (7.6)
Distribution of PSA, n (%)
>4, ≤6 3,009 (49.3)
>6, ≤10 1,733 (28.4)
>10, ≤20 864 (14.2)
>20, ≤50 333 (5.5)
>50 160 (2.6)
Secondary screenees, n (%)
Group I facilitiesa) 2,017 (33.1)
Group II facilitiesb) 4,080 (66.9)
CDR, cancer detection rate; PSA, prostate-specific antigen. 
a)Hospitals or clinics in Ibaraki prefecture with less than 100 patients. 
b)Hospitals or clinics with 100 or more patients in Ibaraki prefecture, 
and those located outside Ibaraki prefecture. 
Table 2. The factors related with cancer detection rates at sec-
ondary screening
Variable OR (95% CI) P-value
Age (yr) <0.001
<70 1
≥70 1.28 (1.11–1.47)
Serum PSA level (ng/mL) <0.001
4–6 1
≥6 5.79 (4.90–6.86)
Facilities <0.001
Group I 1
Group II 2.14 (1.82–2.54)
OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen. 
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in secondary screening of participants with high PSA levels, 
as shown in Table 2. To elucidate why the CDRs in groups I 
and II facilities were different, participants were stratified by 
PSA levels (Fig. 4). Interestingly, the CDRs of group II facili-
ties increased according to PSA levels in a similar pattern in 
all three municipality groups, whereas the CDRs in the group 
I facilities were significantly lower than the group II facilities 
for participants with more than 20 ng/mL PSA in moderate 
and low CDR municipality groups. In high CDR municipality 
groups, the CDRs for participants with 10–20 ng/mL of PSA 
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Fig. 1. The observed/expected number of prostate cancer (PCA) patients who attended secondary screening in each municipality. Thir-
ty-six municipalities were divided to three groups according to the observed-to-expected (O/E) ratios of numbers of PCA. CDR, cancer 
detection rate.
Fig. 2. Distribution of patient age (A), serum prostate-specific antigen (PSA) levels (B), and referral facilities (C) among three munici-
pality groups divided by cancer detection rate (CDR). Significant differences in referral facility among the three groups were noted 
(C). There was no significant difference in patient age (A) and serum PSA level (B). *P<0.05. **P<0.01. 
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were significantly different between groups I and II facilities. 
DISCUSSION
In the present study, we analyzed the results of 6,099 men 
who underwent secondary screening in the practice-based 
PCA screening program of Ibaraki Prefecture and demon-
strated that CDRs at the secondary screening varied largely 
among municipalities from 5.6% to 35.0%. These variations 
were also observed when the age distributions were adjusted. 
Similarly, the 2005 annual report of JFPR revealed that CDRs 
at the primary screening varied from 0% to 5.1% among 218 
municipalities over Japan [3]. These data indicate that this 
variation of CDR at secondary screening is an important issue 
for PCA screening not only in Ibaraki Prefecture but also all 
over Japan. Generally, CDRs at the secondary screening could 
be affected by several factors including age distribution, PSA 
distribution, and the rate of prostate biopsies performed. To 
elucidate the factors contributing to the wide variations of 
CDR might provide crucial information for improving CDR at 
secondary screening.
 In the present study, we demonstrated several important 
findings. First, significant differences in CDRs were observed 
between facilities at the secondary screening. The CDRs in 
group I facilities, which had accumulated fewer than 100 par-
ticipants in 10 years, were approximately half of those in group 
II facility. This tendency was observed in all three municipal-
ity groups. Furthermore, the multivariate analysis demon-
strated a significant association between facility groups at 
secondary screening and CDRs, indicating that it was an in-
dependent predicting factor for PCA detection as well as age 
and serum PSA levels. 
 The second important finding was that group II facilities 
demonstrated a significantly higher rate of prostate biopsy 
rather than group I facilities in accordance with CDRs be-
tween facility groups, but a similar rate of positive biopsies. 
In the European Randomized Study of Screening for Prostate 
Cancer (ERSPC), Otto et al. [5] revealed that differences in 
protocol rather than a true underlying incidence of PCA could 
contribute to the high variation of CDR among European 
countries, although it was not restricted to biopsy rate. These 
observations suggested that the variations in CDRs were as-
sociated with biopsy rates. 
 Several factors have been reported to be related to the rates 
of prostate biopsy for patients with high PSA. In the United 
States, significant variations of accessibility or compliance 
to PCA screening were observed among race, ethnicity, and 
residency. Fedewa et al. [6] reported that insurance status was 
strongly associated with PCA disease severity and concluded 
that the lack of access to services such as PSA screening might 
be responsible for the variations of disease severity. Also, in 
another large screening trial, non-Hispanic black men had 
significantly lower access to diagnostic care after a positive 
PSA screening [7]. A nationwide multicenter study in Korea 
revealed a significantly lower incidence of biopsy in local clin-
ics than in general hospitals (21.6% vs. 66.2%) [8]. In Japan, 
where a national health insurance system is established, a 
disadvantage from insurance status can be almost negligible. 
One plausible explanation for variations in biopsy rates is 
that accessibility to specialized care differs after positive PSA 
screening. These data suggested the necessity of establishing 
a referral system for biopsy in the screening program.
 Another possible explanation for wide variations of prostate 
biopsy is a more conservative attitude toward making the de-
Fig. 4. Difference in cancer detection rate (CDR) between groups I and II facilities according to serum prostate-specific antigen (PSA) 
levels. **P<0.01.
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cision for a prostate biopsy in general practice compared to an 
academic setting. In ERSPC, the average rate complying with 
a biopsy recommendation is as high as 85.6% [9]. Although 
not necessarily directly comparable, the overall biopsy rate at 
the secondary screening in the present study was limited to 
38%. This biopsy rate was also somewhat lower than the JFPR 
data. According to the 2005 JFPR report, the overall biopsy 
rate of second screening participants was 51.9%. But, impor-
tantly, the JFPR report also showed a large regional difference 
in biopsy rates at secondary screening; it differed from 0% to 
100% among municipalities. A similar difference in compli-
ance with the biopsy recommendation was observed in an 
active surveillance program. The reported first biopsy rate 
was as high as 80% in the PRIAS study [10]. In contrast, Lee et 
al. [11] demonstrated a 53% compliance rate within one year 
in a U.S. Veterans Affairs population. Multiple factors are sup-
posed to underlie the lower compliance in general practice, 
such as less patient education and poorer physician-patient 
communication.
 The present retrospective study has several limitations. The 
detailed information such as procedure of informed consent, 
the intensity of recommendation for prostate biopsy and bi-
opsy strategy in each facility was lacking. Those factors can 
directly affect CDR of each facility. In addition, unfortunately 
in Ibaraki Prefecture, the reliable information on regional dif-
ference in exposure rate for PSA screening was not available. 
If regional difference of PSA exposure rate exists, it can affect 
regional CDRs in PCA screening. Next, biopsy rate and CDR 
were estimated on screening reports from facilities where 
PSA-positive patients had first visited. Therefore, it is possible 
that some patients transferred to another hospital for further 
evaluation. This may result in underestimation of biopsy rate 
and CDR. This database does not include detailed informa-
tion on patients such as comorbidity or other reasons to avoid 
biopsy. Finally, if patients and physicians decided to follow up 
a serum PSA at the first visit, follow-up data was not available 
in the present study. Therefore, there is a possibility that some 
nonbiopsied patients were finally diagnosed with PCA at fur-
ther follow-up. 
 In conclusion, we demonstrated that CDR varied greatly 
among municipalities, and that the variation in CDRs was 
associated with biopsy rates but not a difference in target 
populations among municipalities in Ibaraki Prefecture. The 
different decisions made for prostate biopsy are considered 
to be responsible for the variation of biopsy rates.
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